Abstract
Mast cells are critical effectors in inflammatory diseases, including cardiovascular and metabolic diseases and their associated complications. These cells exert their physiological and pathological activities by releasing granules containing histamine, cytokines, chemokines, and proteases, including mast cell-specific chymases and tryptases. Several recent human and animal studies have shown direct or indirect participation of mast cell-specific proteases in atherosclerosis, abdominal aortic aneurysms, obesity, diabetes, and their complications. Animal studies have demonstrated the beneficial effects of highly selective and potent chymase and tryptase inhibitors in several experimental cardiovascular and metabolic diseases. In this review, we summarize recent discoveries from in vitro cell-based studies to experimental animal disease models, from protease knockout mice to treatments with recently developed selective and potent protease inhibitors, and from patients with preclinical disorders to those affected by complications. We hypothesize that inhibition of chymases and tryptases would benefit patients suffering from cardiovascular and metabolic diseases.
Keywords: Mast cell, chymase, tryptase, atherosclerosis, abdominal aortic aneurysms, obesity, diabetes.
Current Pharmaceutical Design
Title:Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Volume: 19 Issue: 6
Author(s): Aina He and Guo-Ping Shi
Affiliation:
Keywords: Mast cell, chymase, tryptase, atherosclerosis, abdominal aortic aneurysms, obesity, diabetes.
Abstract: Mast cells are critical effectors in inflammatory diseases, including cardiovascular and metabolic diseases and their associated complications. These cells exert their physiological and pathological activities by releasing granules containing histamine, cytokines, chemokines, and proteases, including mast cell-specific chymases and tryptases. Several recent human and animal studies have shown direct or indirect participation of mast cell-specific proteases in atherosclerosis, abdominal aortic aneurysms, obesity, diabetes, and their complications. Animal studies have demonstrated the beneficial effects of highly selective and potent chymase and tryptase inhibitors in several experimental cardiovascular and metabolic diseases. In this review, we summarize recent discoveries from in vitro cell-based studies to experimental animal disease models, from protease knockout mice to treatments with recently developed selective and potent protease inhibitors, and from patients with preclinical disorders to those affected by complications. We hypothesize that inhibition of chymases and tryptases would benefit patients suffering from cardiovascular and metabolic diseases.
Export Options
About this article
Cite this article as:
He Aina and Shi Guo-Ping, Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/1381612811319060012
DOI https://dx.doi.org/10.2174/1381612811319060012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets A Case of Pulmonary Tuberculosis Mimicking as Diffuse Alveolar Hemorrhage: A Case Report
New Emirates Medical Journal Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets HDL Stimulates apoM Secretion
Protein & Peptide Letters A Blood Vessel Deformation Model Based Virtual-reality Simulator for the Robotic Catheter Operating System
Neuroscience and Biomedical Engineering (Discontinued) Takotsubo Cardiomyopathy
Current Pharmaceutical Design Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Significant Association of CXCL12 rs1746048 with LDL-C Level in Intracranial Aneurysms
Current Neurovascular Research Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Current Alzheimer Research Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry